Osteoporosis: Understanding key risk factors and therapeutic options

Physician and Sportsmedicine

Volumn 28, Issue 2, 2000, Pages 69-84

  Beck, Belinda R ^b   Shoemaker, M Rebecca ^b  

^a GRIFFITH UNIVERSITY   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; SELECTIVE ESTROGEN RECEPTOR MODULATOR; VITAMIN D;

BONE MASS; CALCIUM INTAKE; EXERCISE; FRACTURE; HUMAN; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; REVIEW;

EID: 0033972462     PISSN: 00913847     EISSN: None     Source Type: Journal    
DOI: 10.3810/psm.2000.02.695     Document Type: Review

References (6)

1. Beck BR, Marcus R: The impact of physical activity on age-related bone loss, in Rosen CJ, Glowacki J, Bilezikian JP (eds): The Aging Skeleton. San Diego, Academic Press, 1999, pp 467-478
2. Effects of hormone therapy on bone mineral density, results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI. JAMA 1996;276(17):1389-1396
3. Kanis JA, Melton LJ 3rd, Christiansen C, et al: The diagnosis of osteoporosis. J Bone Miner Res 1994;9(8):1137-1141
4. Marcus R, Feldman D, Kelsey JL (eds): Osteoporosis. San Diego, Academic Press, 1996
5. Meunier PJ, Delmas PD, Eastell R, et al: Diagnosis and management of osteoporosis in postmenopausal women: clinical guidelines: International Committee for Osteoporosis Clinical Guidelines. Clin Ther 1999;21(6):1025-1044
6. Pols HA, Felsenberg D, Hanley DA, et al: Multinational, place-bo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in post-menopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 1999;9(5):461-468